World Health Organization Issues Concern Over Severe Shortage of Obesity Jabs
Fewer than a tenth of patients eligible to benefit from obesity jabs like Wegovy are able to get them, states the World Health Organization as it issues its inaugural advice on the therapies.
Considering more than one billion individuals worldwide currently living with obesity, it is urging more widespread and fairer availability to GLP-1 medication.
Based on estimates, more than two billion will be obese by 2030 without intervention.
"The latest guidance recognises that obesity is a chronic disease that can be treated with thorough and ongoing treatment," stated its chief Tedros Adhanom Ghebreyesus.
Significant expense, constrained manufacturing, and supply-chain constraints are significant barriers to broad availability to the treatments that can aid individuals in losing significant body mass, explains the body.
Skinny Jab Supply Crisis
Even in the current most optimistic outlook, the manufacturing of such drugs might only reach about 100 million people – under 10% of eligible patients, per the health organization.
The advice calls on countries and companies to expand availability, through approaches such as voluntary licensing.
A patent on a key compound – the primary ingredient of a leading brand – is due to expire in several countries in 2026.
How Weight-Loss Drugs Operate
GLP-1 drugs replicate a natural hormone to slow digestion, suppress the appetite and boost satiety so users eat less.
Individuals typically begin shedding pounds within a few weeks of starting on the once-weekly jabs.
Evidence points to patients may regain a significant portion a year later of discontinuing the medication, as their usual food cravings come back.
To be above a healthy weight increases your likelihood for experiencing diseases, such as diabetes, cardiovascular issues, brain attack, and specific malignancies.
Excess weight affects individuals in every country and was responsible for millions of deaths worldwide in 2024, according to the health agency.
